[{"indications": "Indications\u00a0HIV infection in combination with other antiretroviral\r\ndrugs; chronic hepatitis B infection with either compensated\r\nliver disease (with evidence of viral replication, and histologically\r\ndocumented active liver inflammation or fibrosis) or decompensated liver disease", "name": "TENOFOVIR DISOPROXIL With efavirenz and emtricitabine", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.3 Antiviral drugs", "5.3.1 HIV infection", "Nucleoside reverse transcriptase inhibitors", "TENOFOVIR DISOPROXIL", "With efavirenz and emtricitabine"], "cautions": "Cautions\u00a0\n(From Nucleoside reverse transcriptase inhibitors: British National Formulary)\nNucleoside reverse transcriptase inhibitors; also test renal function and serum phosphate before\r\ntreatment, then every 4 weeks (more frequently if at increased risk\r\nof renal impairment) for 1 year and then every 3 months, interrupt treatment if renal function deteriorates or serum phosphate\r\ndecreases; concomitant or recent use of nephrotoxic\r\ndrugs; interactions: Appendix 1 (tenofovir) Chronic hepatits B\u00a0 When treating\r\nchronic hepatitis B with tenofovir, monitor liver function tests every\r\n3 months and viral markers for hepatitis B every 3\u20136 months during\r\ntreatment (continue monitoring for at least 1 year after discontinuation\u2014recurrent\r\nhepatitis may occur on discontinuation)", "side-effects": "Side-effects\u00a0see notes above; also hypophosphataemia; rarely renal failure, proximal renal tubulopathy, nephrogenic\r\ndiabetes insipidus; also reported reduced bone density", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/200890.htm", "doses": ["adult over 18 years, 245\u00a0mg\r\nonce daily", "HIV infection stabilised on antiretroviral therapy for\r\nmore than 3 months, adult over 18 years,\r\n1 tablet once daily", "Name[Atripla\u00ae (Gilead) ] Tablets, pink, f/c, efavirenz 600\u00a0mg,\r\nemtricitabine 200\u00a0mg, tenofovir disoproxil (as fumarate) 245\u00a0mg, net\r\nprice 30-tab pack = \u00a3626.90. \r\n    Label:\r\n    23, 25Dose\u00a0HIV infection stabilised on antiretroviral therapy for\r\nmore than 3 months, adult over 18 years,\r\n1 tablet once dailyMissed dose\u00a0If a dose is more than 12 hours late,\r\nthe missed dose should not be taken and the next dose should be taken\r\nat the normal time"], "pregnancy": "Pregnancy\u00a0see Pregnancy"}, {"indications": "Indications\u00a0HIV infection in combination with other antiretroviral\r\ndrugs; chronic hepatitis B infection with either compensated\r\nliver disease (with evidence of viral replication, and histologically\r\ndocumented active liver inflammation or fibrosis) or decompensated liver disease", "name": "TENOFOVIR DISOPROXIL", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.3 Antiviral drugs", "5.3.1 HIV infection", "Nucleoside reverse transcriptase inhibitors"], "cautions": "Cautions\u00a0\n(From Nucleoside reverse transcriptase inhibitors: British National Formulary)\nNucleoside reverse transcriptase inhibitors; also test renal function and serum phosphate before\r\ntreatment, then every 4 weeks (more frequently if at increased risk\r\nof renal impairment) for 1 year and then every 3 months, interrupt treatment if renal function deteriorates or serum phosphate\r\ndecreases; concomitant or recent use of nephrotoxic\r\ndrugs; interactions: Appendix 1 (tenofovir) Chronic hepatits B\u00a0 When treating\r\nchronic hepatitis B with tenofovir, monitor liver function tests every\r\n3 months and viral markers for hepatitis B every 3\u20136 months during\r\ntreatment (continue monitoring for at least 1 year after discontinuation\u2014recurrent\r\nhepatitis may occur on discontinuation)", "side-effects": "Side-effects\u00a0see notes above; also hypophosphataemia; rarely renal failure, proximal renal tubulopathy, nephrogenic\r\ndiabetes insipidus; also reported reduced bone density", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106524.htm", "doses": ["adult over 18 years, 245\u00a0mg\r\nonce daily", "If a dose is more than 12 hours late,\r\nthe missed dose should not be taken and the next dose should be taken\r\nat the normal time"], "pregnancy": "Pregnancy\u00a0see Pregnancy"}, {"indications": "Indications\u00a0HIV infection in combination with other antiretroviral\r\ndrugs; chronic hepatitis B infection with either compensated\r\nliver disease (with evidence of viral replication, and histologically\r\ndocumented active liver inflammation or fibrosis) or decompensated liver disease", "name": "TENOFOVIR DISOPROXIL With emtricitabine", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.3 Antiviral drugs", "5.3.1 HIV infection", "Nucleoside reverse transcriptase inhibitors", "TENOFOVIR DISOPROXIL", "With emtricitabine"], "cautions": "Cautions\u00a0\n(From Nucleoside reverse transcriptase inhibitors: British National Formulary)\nNucleoside reverse transcriptase inhibitors; also test renal function and serum phosphate before\r\ntreatment, then every 4 weeks (more frequently if at increased risk\r\nof renal impairment) for 1 year and then every 3 months, interrupt treatment if renal function deteriorates or serum phosphate\r\ndecreases; concomitant or recent use of nephrotoxic\r\ndrugs; interactions: Appendix 1 (tenofovir) Chronic hepatits B\u00a0 When treating\r\nchronic hepatitis B with tenofovir, monitor liver function tests every\r\n3 months and viral markers for hepatitis B every 3\u20136 months during\r\ntreatment (continue monitoring for at least 1 year after discontinuation\u2014recurrent\r\nhepatitis may occur on discontinuation)", "side-effects": "Side-effects\u00a0see notes above; also hypophosphataemia; rarely renal failure, proximal renal tubulopathy, nephrogenic\r\ndiabetes insipidus; also reported reduced bone density", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/129299.htm", "doses": ["adult over 18 years, 245\u00a0mg\r\nonce daily", "HIV infection in combination with other antiretroviral\r\ndrugs, adult over 18 years, 1 tablet\r\nonce daily", "Name[Truvada\u00ae (Gilead) ] Tablets, blue, f/c, tenofovir disoproxil (as fumarate) 245\u00a0mg, emtricitabine 200\u00a0mg, net price\r\n30-tab pack = \u00a3418.50. \r\n    Label:\r\n    21, counselling, administrationCounselling\u00a0Patients with swallowing difficulties\r\nmay disperse tablet in half a glass of water, orange juice, or grape\r\njuice (but bitter taste)Dose\u00a0HIV infection in combination with other antiretroviral\r\ndrugs, adult over 18 years, 1 tablet\r\nonce dailyMissed dose\u00a0If a dose is more than 12 hours late,\r\nthe missed dose should not be taken and the next dose should be taken\r\nat the normal time"], "pregnancy": "Pregnancy\u00a0see Pregnancy"}]